The UB-RASDisease project is being carried out at The Flanders Institute for Biotechnology (VIB). Having been awarded an ERC consolidator grant, lasting approximately 5 years, it will look to find ways to defeat RAS-driven disease.

By creating genetically modified mouse models and CRISPR-engineered human cell models they can assess the functional impact of the alterations of the identified machinery as a result of unravelling the molecular machinery controlling RAS ubiquitylation. A subsequent synthetic biologic approach will help them obtain insights into mechanisms by which ubiquitylation modulates RAS interactions.

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment